Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Real Psychiatry 2026
January 23-24, 2026
View More
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
View More
Optimizing Care for Patients With Tardive Dyskinesia
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Cobenfy as Add-On Treatment for Schizophrenia Fails to Meet Primary Endpoint in Phase 3 ARISE Trial
April 22nd 2025Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.
Read More
Examining a Case of Acute Late-Pregnancy Psychosis: How Best to Coordinate Care
Peripartum psychosis is considered a psychiatric emergency. Here is how an interdisciplinary team can provide the best care.
Read More
Additional Positive Data on LB-102 for the Treatment of Acutely Exacerbated Schizophrenia
March 31st 2025LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.
Read More